India's ambition to become more than the world's pharmacy received a timely boost after Fischer Medical Ventures Limited (FMVL) announced that its strategic partner, Nanyang Biologics, had been featured in the opening showcase at NVIDIA GTC Taiwan 2026. The recognition came ahead of the keynote by NVIDIA Founder and Chief Executive Officer Jensen Huang, placing the company's AI-powered molecular research platform, NYB.AI, among a select group of innovators working at the intersection of artificial intelligence and life sciences.

For India, where the pharmaceutical industry is already a global leader in producing affordable medicines, the bigger question is no longer whether the country can manufacture drugs at scale, but whether it can discover the next generation of medicines itself.

Artificial intelligence is increasingly becoming part of that journey. Instead of replacing laboratory scientists, AI helps researchers to analyse vast amounts of biological data, predict how tiny drug molecules may behave, and identify promising candidates before they undergo expensive laboratory tests. Scientists describe this process as molecular modelling—using computers to simulate how molecules interact—allowing researchers to narrow down thousands of possibilities much faster than traditional methods. Research published in journals like Nature Reviews and Drug Discovery has shown that AI can speed up the early stages of drug discovery, but every promising molecule still needs to go through thorough lab tests and clinical trials and get regulatory approval before it can be given to patients.

FMVL says its partnership aims to bring these advanced research capabilities to India while encouraging collaboration between pharmaceutical companies, biotechnology firms, universities and research institutions.

"NYB.AI's recognition at NVIDIA GTC Taiwan 2026 validates the strength of the technology developed by our strategic partner, Nanyang Biologics. "We are proud to work alongside an organisation that is helping redefine AI-driven molecular research, and we look forward to introducing these capabilities to India's scientific and pharmaceutical communities," said Ravindran Govindan, Chairman of Fischer Medical Ventures Limited.

He added, "India possesses exceptional scientific talent, a globally respected pharmaceutical industry and a rich heritage of botanical knowledge. By combining these strengths with advanced artificial intelligence, we have an opportunity to accelerate innovation, strengthen research capabilities, and contribute to the discovery of new therapies that address unmet medical needs."

At the heart of the collaboration is Vecura, a 'no-code' molecular research platform that uses advanced AI models to simulate molecular behaviour and conduct large-scale virtual experiments, enabling researchers to evaluate potential compounds before moving to physical laboratories.

"Our partnership with Nanyang Biologics is about more than bringing advanced technology to India; it is about building an AI-enabled life sciences ecosystem that strengthens collaboration between academia, research institutions and the pharmaceutical industry," said Svetlana Rao Raviwada, Whole-Time Executive Director, Fischer Medical Ventures Limited.

If such collaborations translate into validated scientific discoveries, they could help India evolve from being largely a manufacturer of medicines into a global centre for AI-enabled pharmaceutical innovation—an achievement whose ultimate value will be measured not by technology alone but by better treatments reaching patients faster and more efficiently.